- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01769027
Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS (ATIVPANDAS)
Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS
An increasing body of evidence indicates that an immune basis might underline a number of pediatric neuropsychiatric disorders. Research studies found a subgroup of children who had Obsessive compulsive (OCD) and/or tic disorders following a Group A beta-hemolytic streptococcal (GAS) infection. The subgroup is identified by the acronym, PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. More recently, several PANDAS variants have been described, including adult-onset variant. There are many evidences that OCD/tic symptoms could be due to an immunologic reaction against brain tissues following a streptococcal infection.
The purpose of this study is to know if sertraline (one of the SSRI approved by FDA to improve OCD/tic symptoms in these patients) plus antibiotic (benzathine penicillin G or azithromycin in case of penicillin allergy) is more effective than SSRI only.
Patients who will not respond to antibiotic will be treated with intravenous immunoglobulin (IVIG) in order to inactivate the immune reaction versus brain tissues.(No treatment response is based on the lack of a Y-BOCS score improvement of at least 35%).
Objectives:
- To determine the safety and efficacy of SSRI+AB compared to SSRI only.
- To test the safety and additional beneficial effects of high dose of IVIG on antibiotic prophylaxis for the treatment of OCD symptoms in non-responders patients with PANDAS.
Study methodology:
- Participants will be screened to obtain medical history and other information at Neurologic and Psychiatric Sciences Department of Florence University Hospital and at Paris-est University.
- Participants will receive a treatment of either SSRI+AB or SSRI+placebo for 12 weeks (double-blind randomized trial)
- Patients who will not respond to AB will be admitted to the hospital to receive IVIG for 5 days, for 5 consecutive months.
- Follow-up visits will take place 3 and 6 months after the first evaluation, followed by 6 months follow-ups for 3 additional years.
Blood samples (including blood cytokine determination), ECG, Doppler and 2-dimensional echocardiogram EEG, imaging studies (2 tesla MRI), and other tests will be performed both before and after the treatment with SSRI+AB or SSRI+placebo and in case also after IVIG treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Inclusion criteria for PANDAS subjects are:
- Ages 4 -40 years
Presence of DSM-IV-R obsessive compulsive disorder or tic disorder and at least two of the following:
- Anxieties e.g. new onset separation anxiety
- Sensory abnormalities (tactile/auditory/visual defensiveness or visual misperceptions)
- Behavioral Regression (e.g. new onset impulsivity, hyperactivity, meltdowns)
- Deterioration in school performance or in handwriting
- Emotional lability and/or depression
- Urinary symptoms (frequent urination or enuresis)
- Sleep disturbances
- Anorexia
- Sudden onset of symptoms or episodic course of symptom severity following infections.
- Symptoms are of moderate severity with Yale-Brown Obsessive Compulsive Scale (Y-BOCS) (or with the children's version for subjects below 16 years of age) of more or equal to 16 and/or Yale Global Tic Severity Scale (YGTSS) of more or equal to 21 and with significant impairment (CGI of moderate or worse).
- Laboratory documentation of infection as documented by at least two of these: positive throat culture, documented rise in one or more anti-GAS antibody titers such as anti-streptolysin O, anti-streptococcal DNAaseB.
Exclusion criteria for all subjects are: non-tic neurologic disorder, presence of immunologic disorder, presence of serious medical illness, IgA deficiency (< 20mg/dL), hyperviscosity syndromes, psychotropic therapy.
Interventions:
All patients will be treated with sertraline (to a maximum of 200 mg/day. This study will involve a 12 week double-blind, placebo-controlled, randomized trial with benzathine penicillin G (1.200.000 U every 3 weeks) or azithromycin (500 mg/week) in case of penicillin allergy. Non-responders patients will be treated with IVIG (2 g/kg of body weight over 5 days, for 5 consecutive months)
Outcomes:
Primary Outcome Measures:
- Significant reduction of OC/tic symptoms severity, as assessed by YBOCS/YGTSS, compared to placebo, after antibiotic prophylaxis. [ Time Frame: 6 months ]
- Significant reduction of OC/tic symptoms severity, as assessed by YBOCS/YGTSS, compared to placebo, after IVIG treatment. [ Time Frame: 6 months ]
Secondary Outcome Measures:
- The degree of treatment response is expected to correlate with the percentage reduction in antibodies titers following IVIG administration. [ Time Frame: 6 months]
- The degree of treatment response is also expected to correlate with decreased inflammation in specific regions of the brain, as demonstrated by macroscopic changes and microstructural alterations on MRI and serum and CSF cytokines and chemokines [ Time Frame: 6 months ]
Expected impact:
- To clarify the utility of antibiotic and IVIG therapy in PANDAS and how the IVIG produce their effects.
- To individualize the treatment.
- To disseminate new data for the treatment of PANDAS.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Stefano Pallanti, MD, PhD
- Phone Number: +390557949707
- Email: stefanopallanti@yahoo.it
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages 4 -40 years
Presence of DSM-IV-R obsessive compulsive disorder or tic disorder and at least two of the following:
- Anxieties e.g. new onset separation anxiety
- Sensory abnormalities (tactile/auditory/visual defensiveness or visual misperceptions)
- Behavioral Regression (e.g. new onset impulsivity, hyperactivity, meltdowns)
- Deterioration in school performance or in handwriting
- Emotional lability and/or depression
- Urinary symptoms (frequent urination or enuresis)
- Sleep disturbances
- Anorexia
- Sudden onset of symptoms or episodic course of symptom severity following infections
- Laboratory documentation of infection
Exclusion Criteria:
- Exclusion criteria for all subjects are: non-tic neurologic disorder, presence of immunologic disorder, presence of serious medical illness, IgA deficiency (< 20mg/dL), hyperviscosity syndromes, psychotropic therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: SSRI+AB
Intervention: sertraline+antibiotic (penicillin/azithromycin) 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day)and one antibiotic ( benzathine penicillin G 1.200.000
U every 3 weeks or, in case of allergy, azithromycin 500 mg/week ).
Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
|
12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week. Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
Other Names:
Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
Other Names:
|
Placebo Comparator: SSRI+placebo
Intervention: Sertraline+placebo 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and a placebo
|
12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The improvement of OC/tic symptoms will be superior in patients treated with SSRI+AB and in case with IVIG, compared with those treated with SSRI+placebo, as assessed by the YBOCS/YGTSS
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The degree of treatment response is expected to correlate with the percentage reduction in antibodies titers following IVIG administration
Time Frame: 6 months
|
6 months
|
The degree of treatment response is also expected to correlate with decreased inflammation in specific regions of the brain, as demonstrated by macroscopic changes and microstructural alterations on MRI and serum and CSF cytokines and chemokines
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stefano Pallanti, MD; PhD
Publications and helpful links
General Publications
- Snider LA, Lougee L, Slattery M, Grant P, Swedo SE. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biol Psychiatry. 2005 Apr 1;57(7):788-92. doi: 10.1016/j.biopsych.2004.12.035.
- Garvey MA, Perlmutter SJ, Allen AJ, Hamburger S, Lougee L, Leonard HL, Witowski ME, Dubbert B, Swedo SE. A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biol Psychiatry. 1999 Jun 15;45(12):1564-71. doi: 10.1016/s0006-3223(99)00020-7.
- Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet. 1999 Oct 2;354(9185):1153-8. doi: 10.1016/S0140-6736(98)12297-3.
- Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, Lougee L, Dow S, Zamkoff J, Dubbert BK. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry. 1998 Feb;155(2):264-71. doi: 10.1176/ajp.155.2.264. Erratum In: Am J Psychiatry 1998 Apr;155(4):578.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Immunologic Factors
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Sertraline
- Immunoglobulins, Intravenous
- Anti-Bacterial Agents
- Azithromycin
- Penicillins
Other Study ID Numbers
- spallanti
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pandas
-
University of MinnesotaCompletedPANDAS | PANSUnited States
-
University of South FloridaMassachusetts General HospitalCompletedPANDAS | Obsessive Compulsive Disorder (OCD) | PANSUnited States
-
Massachusetts General HospitalRecruitingAutoimmune Diseases | Obsessive-Compulsive Disorder | PANDAS | Anxiety DisorderUnited States
-
Stanford UniversityRecruitingPANDAS | PANS | Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections | Pediatric Acute-Onset Neuropsychiatric SyndromeUnited States
-
National Institute of Mental Health (NIMH)CompletedObsessive-Compulsive Disorder | Children | PANDAS | Autoimmune Disease | Anxiety DisorderUnited States
-
Karolinska InstitutetThe Swedish Research CouncilCompletedPANDAS | Obsessive-compulsive Disorder | Obsessive-compulsive Disorder With Acute Onset | Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections | Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) | Childhood Acute Neuropsychiatric Symptoms (CANS)Sweden
Clinical Trials on Sertraline+Antibiotic (penicillin/azithromycin)
-
National Institute of Allergy and Infectious Diseases...Completed
-
Katarina HedinLund University; Umeå University; Linkoeping UniversityUnknownTonsillitis | Sore ThroatSweden
-
Lihir Medical CentreCentre For International HealthCompletedYaws | Treponema Infection | Neglected Tropical DiseasePapua New Guinea
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI)CompletedPulmonary Disease, Chronic ObstructiveUnited States
-
Imperial College LondonCompletedPharmacokinetics | Penicillin Allergy | Beta Lactam Adverse ReactionUnited Kingdom
-
Ceren Melahat DonmezerCompletedImpacted Wisdom ToothCyprus
-
Beijing Children's HospitalHopital Universitaire Robert-Debre; Shandong University; Rennes University HospitalRecruitingChildren; InfectionChina
-
University of Missouri-ColumbiaCompletedSnoring | Strep ThroatUnited States
-
Holbaek SygehusAase and Ejnar Danielsens Foundation; Region SjællandUnknownPneumonia | Acute Exacerbation of Chronic Obstructive Airways DiseaseDenmark